Extrasolar enigmas: from disintegrating exoplanets to exoasteroids

Thousands of transiting exoplanets have been discovered to date, thanks in great part to the {\em Kepler} space mission. As in all populations, and certainly in the case of exoplanets, one finds unique objects with distinct characteristics. Here we will describe the properties and behaviour of a small group of `disintegrating' exoplanets discovered over the last few years (KIC 12557548b, K2-22b, and others). They evaporate, lose mass unraveling their naked cores, produce spectacular dusty comet-like tails, and feature highly variable asymmetric transits. Apart from these exoplanets, there is observational evidence for even smaller `exo-'objects orbiting other stars: exoasteroids and exocomets. Most probably, such objects are also behind the mystery of Boyajian's star. Ongoing and upcoming space missions such as {\em TESS} and PLATO will hopefully discover more objects of this kind, and a new era of the exploration of small extrasolar systems bodies will be upon us.Comment: Accepted for publication in the book "Reviews in Frontiers of Modern Astrophysics: From Space Debris to Cosmology" (eds Kabath, Jones and Skarka; publisher Springer Nature) funded by the European Union Erasmus+ Strategic Partnership grant "Per Aspera Ad Astra Simul" 2017-1-CZ01-KA203-03556

Beyond equilibrium climate sensitivity

ISSN:1752-0908ISSN:1752-089

Interleukin-10 reduces hyperalgesia and the level of Interleukin-1β in BALB/c mice infected with Leishmania major with no major effect on the level of Interleukin-6

Infection with a high dose of Leishmania major has been shown to induce hyperalgesia in BALB/c mice accompanied by a sustained upregulation of Interleukin-1β (IL-1β) and an early upregulation of Interleukin-6 (IL-6). On the other hand, Interleukin 10 (IL-10) has been demonstrated to be hypoalgesic in other models such as rats exposed to UV rays. In this study, we injected BALB/c mice with a high dose of Leishmania major and treated them with IL-10 (15 ng/animal) for six consecutive days. Hyperalgesia was assessed using thermal pain tests and the levels of IL-1β and IL-6 were also assessed at different post-infection days. Our results show that IL-10 can reduce the Leishmania major-induced hyperalgesia during the treatment period through a direct effect on the levels of IL-1β which seems to play an important role in this hyperalgesia induction since its level was reduced during the period of IL-10 injection and was increased again when this treatment was stopped. On the contrary IL-10 has no direct effect on the levels IL-6 which seems to have no direct role in the induced hyperalgesia. © 2006 Elsevier B.V. All rights reserved

Leishmania major: Low infection dose causes short-lived hyperalgesia and cytokines upregulation in mice

Neural involvement was traditionally associated with leprosy. However, more recent studies have shown the presence of a persistent hyperalgesia in cutaneous leishmaniasis caused by the infection of BALB/c mice with a high dose of Leishmania major. In this study, we report the presence of hyperalgesia within the first two weeks of infection caused by a low dose of the parasite. Using BALB/c mice, we demonstrate the presence of hyperalgesia during the first 10 days of infection as assessed by thermal pain tests. After 10 days these decreased pain thresholds start to recover resulting in similar levels to those in uninfected controls during the third week of infection. This hyperalgesia is accompanied by a sustained upregulation of interleukin-1β (IL-1β) and an early upregulation of interleukin-6 (IL-6) which is restored to normal levels after five days of infection. In conclusion, this study shows that, during early infection, the low dose of L. major causes hyperalgesia accompanied by an upregulation of IL-1β and IL-6 and that these effects are reversed within the first two weeks of infection. © 2006 Elsevier Inc. All rights reserved